Cancer-related inflammation: Common themes and therapeutic opportunities

Seminars in Cancer Biology

Volumn 22, Issue 1, 2012, Pages 33-40

  Balkwill, Frances R ^a   Mantovani, Alberto ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Chemokines; Cytokines; Inflammation; Macrophages; Tumor microenvironment

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BCG VACCINE; BIOLOGICAL MARKER; CCL28 CHEMOKINE; CELECOXIB; CHEMOKINE; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4 ANTIBODY; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CP 870893; DRUG ANTIBODY; ETANERCEPT; GEMCITABINE; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 6 ANTIBODY; MACROPHAGE DERIVED CHEMOKINE; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PLACEBO; PLERIXAFOR; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SILTUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTINIC KERATOSIS; ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RESEARCH; CASTRATION RESISTANT PROSTATE CANCER; CELL POLARITY; CELL SPECIFICITY; CHEMOKINESIS; CLINICAL EFFECTIVENESS; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG CYTOTOXICITY; DRUG EFFICACY; EPITHELIUM TUMOR; HUMAN; INFLAMMATORY CELL; INFLAMMATORY DISEASE; KIDNEY CANCER; LYMPHOMA; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOMA; NEOPLASM; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PRIMARY TUMOR; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SQUAMOUS CELL CARCINOMA; TARGET CELL; TREATMENT PLANNING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

CYTOKINES; FIBROBLASTS; HUMANS; INFLAMMATION; MACROPHAGES; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84857141296     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2011.12.005     Document Type: Review

References (104)

1. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
2. Sodir N.M., Swigart L.B., Karnezis A.N., Hanahan D., Evan G.I., Soucek L. Endogenous Myc maintains the tumor microenvironment. Genes Dev 2011, 25:907-916.
3. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
4. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11:889-896.
5. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22:231-237.
6. Qian B.Z., Pollard J.W. Macrophage diversity enhances tumor progression and metastasis. Cell 2010, 141:39-51.
7. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008, 8:958-969.
8. Geissmann F., Manz M.G., Jung S., Sieweke M.H., Merad M., Ley K. Development of monocytes, macrophages, and dendritic cells. Science 2010, 327:656-661.
9. Movahedi K., Laoui D., Gysemans C., Baeten M., Stange G., Van den Bossche J., et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res 2010, 70:5728-5739.
10. Andreu P., Johansson M., Affara N.I., Pucci F., Tan T., Junankar S., et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 2010, 17:121-134.
11. DeNardo D.G., Barreto J.B., Andreu P., Vasquez L., Tawfik D., Kolhatkar N., et al. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 16:91-102.
12. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard C., et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008, 9:1225-1235.
13. Ammirante M., Luo J.L., Grivennikov S., Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010, 464:302-305.
14. Schioppa T., Moore R., Thompson R.G., Rosser E.C., Kulbe H., Nedospasov S., et al. B regulatory cells and the tumor-promoting actions of TNF-{alpha} during squamous carcinogenesis. Proc Natl Acad Sci U S A 2011, 108:10662-10667.
15. Olkhanud P.B., Damdinsuren B., Bodogai M., Gress R.E., Sen R., Wejksza K., et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4T cells to T-regulatory cells. Cancer Res 2011, 71:3505-3515.
16. Wong S.C., Puaux A.L., Chittezhath M., Shalova I., Kajiji T.S., Wang X., et al. Macrophage polarization to a unique phenotype driven by B cells. Eur J Immunol 2010, 40:2296-2307.
17. Bottazzi B., Erba E., Nobili N., Fazioli F., Rambaldi A., Mantovani A. A paracrine circuit in the regulation of the proliferation of macrophages infiltrating murine sarcomas. J Immunol 1990, 144:2409-2412.
18. Jenkins S.J., Ruckerl D., Cook P.C., Jones L.H., Finkelman F.D., van Rooijen N., et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011, 332:1284-1288.
19. Hamilton J.A. Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008, 8:533-544.
20. Dvorak H.F. Tumors: wounds that do not heal. New Engl J Med 1986, 315:1650-1656.
21. Erez N., Truitt M., Olson P., Hanahan D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 2010, 17:135-147.
22. Spaeth E.L., Dembinski J.L., Sasser A.K., Watson K., Klopp A., Hall B., et al. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.
23. Elkabets M., Gifford A.M., Scheel C., Nilsson B., Reinhardt F., Bray M.A., et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011, 121:784-799.
24. Kraman M., Bambrough P.J., Arnold J.N., Roberts E.W., Magiera L., Jones J.O., et al. Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha. Science 2010, 330:827-830.
25. Mantovani A., Cassatella M.A., Costantini C., Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011, 11:519-531.
26. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: N1 versus N2 TAN. Cancer Cell 2009, 16:183-194.
27. Nozawa H., Chiu C., Hanahan D. Infiltrating neutrophils mediate the initial angiogenic switch in a mouse model of multistage carcinogenesis. PNAS 2006, 103:12493-12498.
28. Soucek L., Lawlor E.R., Soto D., Shchors K., Swigart L.B., Evan G.I. Mast cells are required for angiogenesis and macropscopic expansion of Myc-induced pancreatic islet tumors. Nat Med 2007, 13:1211-1218.
29. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371.
30. Kulbe H., Thompson R.T., Wilson J., Robinson S.C., Hagemann T., Fatah R., et al. The inflammatory cytokine TNF-a generates an autocrine tumour-promoting network in epithelial ovarian cancer cells. Cancer Res 2007, 67:585-592.
31. Li B., Vincent A., Cates J., Brantley-Sieders D.M., Polk D.B., Young P.P. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res 2009, 69:338-348.
32. Hagemann T., Wilson J., Kulbe H., Charles K., Li F., Pukrop T., et al. TNF-a dependent increased c-Jun and NF-k B activity in tumour cell lines upon co-cultivation with macrophages. J Immunol 2005, 175:1197-1205.
33. Charles K.A., Kulbe H., Soper R., Escorcio-Correia M., Lawrence T., Schultheis A., et al. The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans. J Clin Invest 2009, 119:3011-3023.
34. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., et al. NF-kB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:4461-4466.
35. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
36. Komori J., Marusawa H., Machimoto T., Endo Y., Kinoshita K., Kou T., et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarcinoma. Hepatology 2008, 47:888-896.
37. Kim S., Takahashi H., Lin W-W., Descargues P., Grivennikov S., Kim Y., et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457:102-106.
38. Harrison M.L., Obermueller E., Maisey N.R., Hoare S., Edmonds K., Li N.F., et al. Tumor necrosis factor a as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007, 25:4542-4549.
39. Al-Lamki R.S., Sadler T.J., Wang J., Reid M.J., Warren A.Y., Movassagh M., et al. Tumor necrosis factor receptor expression and signaling in renal cell carcinoma. Am J Pathol 2010, 177:943-954.
40. Seike M., Yanaihara N., Bowman E.D., Zanetti K.A., Budhu A., Kumamoto K., et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. JNCI 2007, 99:1257-1269.
41. Cordero J.B., Macagno J.P., Stefanatos R.K., Strathdee K.E., Cagan R.L., Vidal M. Oncogenic Ras diverts a host TNF tumor suppressor activity into tumor promoter. Dev Cell 2010, 18:999-1011.
42. Vidal M., Cagan R.L. Drosophila models for cancer research. Curr Opin Genet Dev 2006, 16:10-16.
43. Naugler W.E., Karin M. The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med 2008, 14:109-119.
44. Grivennikov S., Karin E., Terzic J., Mucida D., Yu G-Y., Vallabhapurapu S., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113.
45. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
46. Ancrile B., Lim K-H., Counter C.M. Oncogenic Ras-induced secretion of IL-6 is required for tumorigenesis. Genes Dev 2007, 21:1714-1719.
47. Shain K.H., Yarde D.N., Meads M.B., Huang M., Jove R., Hazlehurst L.A., et al. β1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009, 69:1009-1015.
48. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K.H., Elsharkawy A.M., et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007, 317:121-124.
49. Gao D., Nolan D.J., Mellick A.S., Bambino K., McDonnell K., Mittal V. Endothelial progenitor cells control the angiogen in switch in mouse lung metastasis. Science 2008, 319:195-198.
50. Ara T., Song L., Shimada H., Keshelava N., Russell H.V., Metelitsa L.S., et al. Interleukin-6 in the bone marrow microenvironment promotes the growth and survival of neuroblastoma cells. Cancer Res 2009, 69:329-337.
51. Duan Z., Foster R., Bell D.A., Mahoney J., Wolak K., Vaidya A., et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006, 12:5055-5063.
52. Lo C.W., Chen M.W., Hsiao M., Wang S., Chen C.A., Hsiao S.M., et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71:424-434.
53. Nilsson M.B., Langley R.R., Fidler I.J. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800.
54. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., Wang R-F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. PNAS 2008, 105:15505-15510.
55. Lutgendorf S.K., Weinrib A.Z., Penedo F., Russell D.W., DeGeest K., Costanzo E.S., et al. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J Clin Oncol 2008, 26:4820-4827.
56. Scambia G., Testa U., Panici P.B., Foti E., Martucci R., Gadducci A., et al. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354-356.
57. Plante M., Rubin S.C., Wong G.Y., Federici M.G., Finstad C.L., Gastl G.A. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888.
58. Saccani A., Schioppa T., Porta C., Biswas S.K., Nebuloni M., Vago L., et al. p50 nuclear factor-kappaB overexpression in tumor-associated macrophages inhibits M1 inflammatory responses and antitumor resistance. Cancer Res 2006, 66:11432-11440.
59. Coffelt S.B., Marini F.C., Watson K., Zwezdaryk K.J., Dembinski J.L., LaMarca H.L., et al. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Proc Natl Acad Sci U S A 2009, 106:3806-3811.
60. Anglesio M.S., George J., Kulbe H., Friedlander M.L., Rischin D., Lemech C., et al. Il6-Stat3-Hif signalling and therapeutic response to the angiogenesis inhibitor, Sunitinib, in ovarian clear cell cancer. Clin Cancer Res 2011, 17:2538-2548.
61. Langowski J.L., Zhang X., Lingling W., Mattson J.D., Chen T., Smith K., et al. IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465.
62. Mantovani A., Savino B., Locati M., Zammataro P.A., Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010, 21:27-39.
63. Vetrano S., Borroni E.M., Sarukhan A., Savino B., Bonecchi R., Correale C., et al. The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 2010, 59:197-206.
64. Qian B.Z., Li J., Zhang H., Kitamura T., Zhang J., Campion L.R., et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011, 475:222-225.
65. Bottazzi B., Polentarutti N., Acero R., Balsari A., Boraschi D., Ghezzi P., et al. Regulation of the macrophage content of neoplasms by chemoattractants. Science 1983, 220:210-212.
66. Nibbs R.J., Gilchrist D.S., King V., Ferra A., Forrow S., Hunter K.D., et al. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J Clin Invest 2007, 117:1884-1892.
67. Zhang J., Patel L., Pienta K.J. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 2010, 21:41-48.
68. De Monte L., Reni M., Tassi E., Clavenna D., Papa I., Recalde H., et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 2011, 208:469-478.
69. Facciabene X., Peng I.S., Hagemann K., Balint A., Barchetti L.P., Wang P.A., et al. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 2011, 475:226-230.
70. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.C., et al. 'Re-educating' tumor-associated macrophages by targeting NF-kB. J Exp Med 2008, 205:1261-1268.
71. Beatty G.L., Chiorean E.G., Fishman M.P., Saboury B., Teitelbaum U.R., Sun W., et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 2011, 331:1612-1616.
72. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 2008, 117:244-279.
73. van Rhee F., Fayad L., Voorhees P., Furman R., Lonial S., Borghaei H., et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010, 28:3701-3708.
74. Dorff T.B., Goldman B., Pinski J.K., Mack P.C., Lara P.N., Van Veldhuizen P.J., et al. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 2010, 16:3028-3034.
75. Rozel S., Galban C.J., Nicolay K., Lee K.C., Sud S., Neeley C., et al. Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model. J Cell Biochem 2009, 107:58-64.
76. Garber K. First results for agents targeting cancer-related inflammation. JNCI 2009, 101:1110-1112.
77. Ito A., Ishida T., Yano H., Inagaki A., Suzuki S., Sato F., et al. Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rgamma(null) mouse model. Cancer Immunol Immunother 2009, 58:1195-1206.
78. Kim S.Y., Lee C.H., Midura B.V., Yeung C., Mendoza A., Hong S.H., et al. Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases. Clin Exp Metastasis 2008, 25:201-211.
79. Porvasnik S., Sakamoto N., Kusmartsev S., Eruslanov E., Kim W.J., Cao W., et al. Effects of CXCR4 antagonist CTCE-9908 on prostate tumor growth. Prostate 2009, 69:1460-1469.
80. Liles W.C., Broxmeyer H.E., Rodger E., Wood B., Hubel K., Cooper S., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
81. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009, 77:1655-1664.
82. Zitvogel L., Kepp O., Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010, 140:798-804.
83. Ma Y., Aymeric L., Locher C., Mattarollo S.R., Delahaye N.F., Pereira P., et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med 2011, 208:491-503.
84. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
85. Ghiringhelli F., Apetoh L., Tesniere A., Aymeric L., Ma Y.-Y., Ortiz C., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
86. Swann J.B., Vesely M.D., Silva A., Sharkey J., Akira S., Schreiber R.D., et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. PNAS 2008, 105:652-656.
87. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. American Association for Cancer Research. Cancer Discov 2011, 2-16.
88. Meng Y., Beckett M.A., Liang H., Mauceri H.J., van Rooijen N., Cohen K.S., et al. Blockade of tumor necrosis factor alpha signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 2010, 70:1534-1543.
89. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009, 10:501-507.
90. Rothwell P.M., Fowkes F.G., Belch J.F., Ogawa H., Warlow C.P., Meade T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011, 377:31-41.
91. Guerra C., Collado M., Navas C., Schuhmacher A.J., Hernandez-Porras I., Canamero M., et al. Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 2011, 19:728-739.
92. Elmets C.A., Viner J.L., Pentland A.P., Cantrell W., Lin H.Y., Bailey H., et al. Chemoprevention of nonmelanoma skin cancer with celecoxib: a randomized, double-blind, placebo-controlled trial. J Natl Cancer Inst 2010, 102:1835-1844.
93. Moore R., Owens D., Stamp G., East N., Holdworth H., Arnott C., et al. Tumour necrosis factor-a deficient mice are resistant to skin carcinogenesis. Nat Med 1999, 5:828-831.
94. Fujiki H., Suganuma M., Kurusu M., Okabe S., Imayoshi Y., Taniguchi S., et al. New TNF-a releasing inhibitors as cancer preventive agents from traditional herbal medicine and combination cancer prevention study with EGCG and sulindac or tamoxifen. Mutat Res 2003, 523:119-125.
95. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006, 295:2275-2285.
96. Askling J., Bongartz T. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008, 20:334-339.
97. Lust J.A., Lacy M.Q., Zeldenrust S.R., Dispenzieri A., Gertz M.A., Witzig T.E., et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 2009, 84:114-122.
98. Dinarello C.A. Anti-inflammatory agents: present and future. Cell 2010, 140:935-950.
99. Anderson G.M., Nakada M.T., DeWitte M. Tumor necrosis factor-a in the pathogenesis and treatment of cancer. Curr Opin Pharmacol 2004, 4:314-320.
100. Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 91:1227.
101. Stark J.R., Li H., Kraft P., Kurth T., Giovannucci E.L., Stampfer M.J., et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009, 124:2683-2689.
102. Kornblau S.M., McCue D., Singh N., Chen W., Estrov Z., Coombes K.R. Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood 2010, 116:4251-4261.
103. Christensen E., Pintilie M., Evans K.R., Lenarduzzi M., Menard C., Catton C.N., et al. Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clin Cancer Res 2009, 15:5576-5583.
104. Burgdorf S.K., Claesson M.H., Nielsen H.J., Rosenberg J. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. Acta Oncol 2009, 1-8.